Core Insights - Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on oncology, specifically targeting solid tumor cancers with the mutated KRAS oncogene [3]. Group 1: Company Presentation - Silexion management will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025, from 2:30 to 2:55 PM ET [2]. - The presentation will be led by Ilan Hadar, CEO, and Mirit Horenshtein-Hadar, CFO, at Florida Atlantic University Conference Center, Boca Raton, FL [2]. - Management will be available for one-on-one meetings during the conference, and interested parties can arrange meetings through their conference representative [2]. Group 2: Clinical Development - Silexion is dedicated to developing innovative treatments for solid tumor cancers, particularly those with the mutated KRAS oncogene, which is the most common oncogenic gene driver in human cancers [3]. - The company has conducted a Phase 2a clinical trial for its first-generation product, which showed a positive trend compared to chemotherapy alone [3]. - Silexion is focused on advancing its lead product candidate for locally advanced pancreatic cancer [3].
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference